HK1121041A1 - Novel use of anti il-1beta antibodies - Google Patents
Novel use of anti il-1beta antibodiesInfo
- Publication number
- HK1121041A1 HK1121041A1 HK09100171.2A HK09100171A HK1121041A1 HK 1121041 A1 HK1121041 A1 HK 1121041A1 HK 09100171 A HK09100171 A HK 09100171A HK 1121041 A1 HK1121041 A1 HK 1121041A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- novel use
- 1beta antibodies
- 1beta
- antibodies
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73043505P | 2005-10-26 | 2005-10-26 | |
US74212505P | 2005-12-02 | 2005-12-02 | |
PCT/US2006/041479 WO2007050607A2 (en) | 2005-10-26 | 2006-10-24 | Novel use of il-1beta compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1121041A1 true HK1121041A1 (en) | 2009-04-17 |
Family
ID=37806690
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09100171.2A HK1121041A1 (en) | 2005-10-26 | 2009-01-07 | Novel use of anti il-1beta antibodies |
HK15105300.7A HK1204767A1 (en) | 2005-10-26 | 2015-06-03 | Treatment of familial mediterranean fever with anti il-1b antibodies il-1b |
HK18111596A HK1252316A1 (zh) | 2005-10-26 | 2018-09-10 | IL-1β抗體的用途 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105300.7A HK1204767A1 (en) | 2005-10-26 | 2015-06-03 | Treatment of familial mediterranean fever with anti il-1b antibodies il-1b |
HK18111596A HK1252316A1 (zh) | 2005-10-26 | 2018-09-10 | IL-1β抗體的用途 |
Country Status (29)
Country | Link |
---|---|
US (8) | US8105587B2 (ja) |
EP (5) | EP3332807B1 (ja) |
JP (4) | JP2009513645A (ja) |
KR (3) | KR101518064B1 (ja) |
CN (2) | CN102861332A (ja) |
AU (1) | AU2006306280B2 (ja) |
BR (1) | BRPI0617830B8 (ja) |
CA (3) | CA2626214C (ja) |
CY (4) | CY1113378T1 (ja) |
DK (2) | DK2848258T3 (ja) |
ES (3) | ES2662420T3 (ja) |
HK (3) | HK1121041A1 (ja) |
HU (2) | HUE036973T2 (ja) |
IL (4) | IL190545A (ja) |
JO (2) | JO2826B1 (ja) |
LT (3) | LT2848258T (ja) |
LU (2) | LU92326I2 (ja) |
MA (1) | MA29919B1 (ja) |
NO (2) | NO345888B1 (ja) |
NZ (1) | NZ567222A (ja) |
PH (2) | PH12013501287A1 (ja) |
PL (2) | PL2848258T3 (ja) |
PT (2) | PT1940465E (ja) |
RU (2) | RU2468817C2 (ja) |
SI (2) | SI1940465T1 (ja) |
TN (1) | TNSN08189A1 (ja) |
TR (1) | TR201802449T4 (ja) |
TW (3) | TWI388335B (ja) |
WO (1) | WO2007050607A2 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3332807B1 (en) | 2005-10-26 | 2023-02-22 | Novartis AG | Use of anti il-1beta antibodies |
CA3080328C (en) | 2007-05-29 | 2022-06-21 | Novartis Ag | New indications for anti-il-1-beta therapy |
AU2012203931B2 (en) * | 2007-05-29 | 2014-04-24 | Novartis Ag | New indications for anti-IL-I-beta therapy |
EP2293816B1 (en) * | 2008-06-06 | 2012-11-07 | XOMA Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
WO2011032119A1 (en) | 2009-09-14 | 2011-03-17 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
JP2013507929A (ja) * | 2009-10-15 | 2013-03-07 | アボット・ラボラトリーズ | Il−1結合蛋白質 |
PE20130205A1 (es) * | 2010-05-14 | 2013-03-24 | Abbvie Inc | Proteinas de union a il-1 |
SG10201604699VA (en) * | 2010-12-21 | 2016-07-28 | Abbvie Inc | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
CN103649336A (zh) | 2011-05-10 | 2014-03-19 | 雀巢产品技术援助有限公司 | 用于个体化治疗管理的疾病活动性表征方法 |
EP3426775A1 (en) | 2016-03-10 | 2019-01-16 | Novartis AG | Chemically modified messenger rna's |
CA3064529C (en) | 2017-05-31 | 2021-12-14 | Prometheus Biosciences, Inc. | Methods for assessing mucosal healing in crohn's disease patients |
UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER |
JP2021523894A (ja) | 2018-05-09 | 2021-09-09 | ノバルティス アーゲー | カナキヌマブの使用 |
WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
EP3898674A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
BR112021011351A2 (pt) | 2018-12-21 | 2021-11-16 | Novartis Ag | Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica |
TWI793503B (zh) * | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | 抗IL-1β抗體 |
KR20230109107A (ko) * | 2022-01-10 | 2023-07-19 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
EP0690673A4 (en) | 1993-12-14 | 1996-05-29 | Univ Pittsburgh | SYSTEMIC GENETIC TREATMENT OF TISSUE DISEASES |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
JP2003500005A (ja) | 1999-02-10 | 2003-01-07 | インターリューキン ジェネティックス インコーポレイテッド | IL−1β遺伝子の突然変異に基づく治療および診断 |
JP2003505361A (ja) * | 1999-07-16 | 2003-02-12 | レオ・ファーマ・アクティーゼルスカブ | IL−1βおよびTNF−αの抑制剤としてのアミノベンゾフェノン |
WO2001014387A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
EP2241328A1 (en) | 2000-05-12 | 2010-10-20 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
EP1337527B1 (en) | 2000-11-07 | 2009-10-14 | Novartis AG | Indolylmaleimide derivatives as protein kinase c inhibitors |
WO2003010282A2 (en) * | 2001-07-26 | 2003-02-06 | Eli Lilly And Company | Interleukin-1 beta antibodies |
EP1450837A4 (en) | 2001-08-07 | 2006-01-04 | Immunex Corp | INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES |
ES2385823T3 (es) | 2001-12-01 | 2012-08-01 | Iskra Wind Turbines Ltd. | Generador de corriente alterna síncrono que incorpora un mecanismo de frenado |
KR200268109Y1 (ko) | 2001-12-06 | 2002-03-15 | 김정훈 | 편평형 무정류자 진동모터 |
EP2407473A3 (en) | 2002-02-01 | 2012-03-21 | ARIAD Pharmaceuticals, Inc | Method for producing phosphorus-containing compounds |
KR20040094413A (ko) | 2002-02-01 | 2004-11-09 | 오메로스 코포레이션 | 연골 분해를 전신 억제하기 위한 조성물 및 방법 |
KR20040105710A (ko) | 2002-02-11 | 2004-12-16 | 아르키온 라이프 사이언씨즈 엘엘씨 | 정제된 사이토킨 억제인자 |
TWI324064B (en) | 2002-04-03 | 2010-05-01 | Novartis Ag | Indolylmaleimide derivatives |
NZ540427A (en) | 2002-12-09 | 2008-04-30 | Univ Texas | Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3) |
EP1590369B1 (en) * | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
WO2005047906A1 (en) | 2003-11-10 | 2005-05-26 | Vertex Pharmaceuticals Incorporated | Methods for monitoring il-18 |
BRPI0506817A (pt) | 2004-01-12 | 2007-05-29 | Cytopia Res Pty Ltd | inibidores seletivos de quinase |
JP4989456B2 (ja) | 2004-02-26 | 2012-08-01 | ベイラー リサーチ インスティテュート | 関節炎の全身処置のための組成物および方法 |
US7531570B2 (en) | 2004-05-27 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Treatment of diseases using ICE inhibitors |
AU2005249570B2 (en) * | 2004-06-04 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Methods of using IL-1 antagonists to treat autoinflammatory disease |
JP2009501128A (ja) | 2005-01-20 | 2009-01-15 | ユニバーシティー オブ ロチェスター | 炎症疾患および炎症障害の研究および処置のための組成物および方法 |
EP2371967B1 (en) | 2005-03-18 | 2015-06-03 | DSM IP Assets B.V. | Production of carotenoids in oleaginous yeast and fungi |
PL2163562T3 (pl) | 2005-06-21 | 2014-03-31 | Xoma Us Llc | Przeciwciała wiążące IL-1 beta i ich fragmenty |
EP3332807B1 (en) * | 2005-10-26 | 2023-02-22 | Novartis AG | Use of anti il-1beta antibodies |
-
2006
- 2006-10-24 EP EP17199544.2A patent/EP3332807B1/en active Active
- 2006-10-24 ES ES14191582.7T patent/ES2662420T3/es active Active
- 2006-10-24 NZ NZ567222A patent/NZ567222A/en unknown
- 2006-10-24 LT LTEP14191582.7T patent/LT2848258T/lt unknown
- 2006-10-24 WO PCT/US2006/041479 patent/WO2007050607A2/en active Application Filing
- 2006-10-24 EP EP10181100A patent/EP2332577A1/en not_active Withdrawn
- 2006-10-24 PT PT06826560T patent/PT1940465E/pt unknown
- 2006-10-24 KR KR1020087009981A patent/KR101518064B1/ko active IP Right Grant
- 2006-10-24 US US12/090,490 patent/US8105587B2/en active Active
- 2006-10-24 JP JP2008537878A patent/JP2009513645A/ja not_active Withdrawn
- 2006-10-24 ES ES06826560T patent/ES2389110T3/es active Active
- 2006-10-24 PL PL14191582T patent/PL2848258T3/pl unknown
- 2006-10-24 EP EP23155348.8A patent/EP4218815A3/en active Pending
- 2006-10-24 EP EP14191582.7A patent/EP2848258B1/en active Active
- 2006-10-24 BR BRPI0617830A patent/BRPI0617830B8/pt active IP Right Grant
- 2006-10-24 CN CN2012102904088A patent/CN102861332A/zh active Pending
- 2006-10-24 RU RU2008120625/15A patent/RU2468817C2/ru active
- 2006-10-24 DK DK14191582.7T patent/DK2848258T3/en active
- 2006-10-24 TR TR2018/02449T patent/TR201802449T4/tr unknown
- 2006-10-24 KR KR1020177008682A patent/KR20170038131A/ko not_active Application Discontinuation
- 2006-10-24 HU HUE14191582A patent/HUE036973T2/hu unknown
- 2006-10-24 ES ES17199544T patent/ES2944067T3/es active Active
- 2006-10-24 CA CA2626214A patent/CA2626214C/en active Active
- 2006-10-24 CA CA2963828A patent/CA2963828A1/en not_active Abandoned
- 2006-10-24 SI SI200631412T patent/SI1940465T1/sl unknown
- 2006-10-24 NO NO20200810A patent/NO345888B1/no unknown
- 2006-10-24 PT PT141915827T patent/PT2848258T/pt unknown
- 2006-10-24 CN CN200680039395XA patent/CN101291693B/zh active Active
- 2006-10-24 AU AU2006306280A patent/AU2006306280B2/en active Active
- 2006-10-24 SI SI200632245T patent/SI2848258T1/en unknown
- 2006-10-24 PL PL06826560T patent/PL1940465T3/pl unknown
- 2006-10-24 CA CA2898369A patent/CA2898369C/en active Active
- 2006-10-24 KR KR1020147035512A patent/KR101749388B1/ko active IP Right Grant
- 2006-10-24 DK DK06826560.2T patent/DK1940465T3/da active
- 2006-10-24 EP EP06826560A patent/EP1940465B1/en active Active
- 2006-10-25 TW TW095139438A patent/TWI388335B/zh active
- 2006-10-25 TW TW105103583A patent/TWI626056B/zh active
- 2006-10-25 TW TW101132057A patent/TWI537003B/zh active
- 2006-10-29 JO JO2006387A patent/JO2826B1/en active
-
2008
- 2008-03-31 IL IL190545A patent/IL190545A/en active IP Right Grant
- 2008-04-23 MA MA30863A patent/MA29919B1/fr unknown
- 2008-04-25 TN TNP2008000189A patent/TNSN08189A1/en unknown
- 2008-05-23 NO NO20082344A patent/NO345140B1/no unknown
-
2009
- 2009-01-07 HK HK09100171.2A patent/HK1121041A1/xx unknown
-
2011
- 2011-10-27 US US13/283,165 patent/US8409576B2/en active Active
-
2012
- 2012-08-06 RU RU2012133522/15A patent/RU2571563C2/ru active
- 2012-09-24 CY CY20121100867T patent/CY1113378T1/el unknown
-
2013
- 2013-02-26 US US13/777,609 patent/US20130171167A1/en not_active Abandoned
- 2013-03-27 JP JP2013066205A patent/JP6061747B2/ja active Active
- 2013-06-18 PH PH12013501287A patent/PH12013501287A1/en unknown
- 2013-12-05 LU LU92326C patent/LU92326I2/fr unknown
- 2013-12-06 LT LTPA2013026C patent/LTC1940465I2/lt unknown
- 2013-12-13 CY CY2013046C patent/CY2013046I2/el unknown
-
2014
- 2014-03-16 JO JOP/2014/0120A patent/JOP20140120B1/ar active
-
2015
- 2015-06-03 HK HK15105300.7A patent/HK1204767A1/xx unknown
- 2015-07-28 US US14/810,556 patent/US9649377B2/en active Active
- 2015-10-02 JP JP2015196708A patent/JP6286403B2/ja active Active
-
2016
- 2016-05-02 IL IL245387A patent/IL245387B/en active IP Right Grant
-
2017
- 2017-04-11 US US15/484,459 patent/US20170218063A1/en not_active Abandoned
- 2017-08-04 JP JP2017151327A patent/JP2017206552A/ja active Pending
-
2018
- 2018-03-12 CY CY20181100301T patent/CY1120018T1/el unknown
- 2018-03-12 US US15/918,136 patent/US20180201674A1/en not_active Abandoned
- 2018-04-26 IL IL258983A patent/IL258983B/en active IP Right Grant
- 2018-06-11 HU HUS1800025C patent/HUS1800025I1/hu unknown
- 2018-06-11 LU LU00078C patent/LUC00078I2/fr unknown
- 2018-06-12 LT LTPA2018506C patent/LTC2848258I2/lt unknown
- 2018-06-12 CY CY2018018C patent/CY2018018I1/el unknown
- 2018-09-10 HK HK18111596A patent/HK1252316A1/zh unknown
-
2020
- 2020-06-19 US US16/906,118 patent/US20210147533A1/en not_active Abandoned
- 2020-06-23 PH PH12020500559A patent/PH12020500559A1/en unknown
- 2020-09-16 IL IL277406A patent/IL277406A/en unknown
-
2023
- 2023-02-28 US US18/175,849 patent/US20240083997A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252316A1 (zh) | IL-1β抗體的用途 | |
IL266336A (en) | Fixed dose of her antibodies | |
IL191117A0 (en) | Uses of anti-cd40 antibodies | |
AP2552A (en) | P-cadherin antibodies | |
EP1869192A4 (en) | FRAME MIXTURE OF ANTIBODIES | |
PT2343320T (pt) | Anticorpos anti-gitr e as suas utilizações | |
GB0517487D0 (en) | Antibodies | |
GB0505975D0 (en) | Novel use of peptide | |
HK1161122A1 (en) | Use of 24-norudca 24-norudca | |
EP1931370A4 (en) | USE OF DES-ASPARTATE-ANGIOTENSIN I | |
EP1896047A4 (en) | ANTI-GFRALPHA3 ANTIBODIES | |
GB0505489D0 (en) | Antibodies | |
GB0512278D0 (en) | Antibodies | |
GB0505054D0 (en) | Antibodies | |
ZA200802876B (en) | Novel use of IL-1beta compounds | |
GB0506945D0 (en) | Human antibodies | |
GB0502201D0 (en) | Human antibodies | |
GB0503190D0 (en) | Human antibodies | |
GB0519883D0 (en) | Antibodies | |
TWM292440U (en) | Improved structure of sander |